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Abstract: A key parameter in the design of new active compounds is lipophilicity, which influences
the solubility and permeability through membranes. Lipophilicity affects the pharmacodynamic
and toxicological profiles of compounds. These parameters can be determined experimentally or
by using different calculation methods. The aim of the research was to determine the lipophilicity
of betulin triazole derivatives with attached 1,4-quinone using thin layer chromatography in a
reverse phase system and a computer program to calculate its theoretical model. The physiochemical
and pharmacokinetic properties were also determined by computer programs. For all obtained
parameters, the similarity analysis and multilinear regression were determined. The analyses showed
that there is a relationship between structure and properties under study. The molecular docking
study showed that betulin triazole derivatives with attached 1,4-quinone could inhibit selected
SARS-CoV-2 proteins. The MLR regression showed that there is a correlation between affinity scoring
values (∆G) and the physicochemical properties of the tested compounds.
Keywords: 1,4-quinone; betulin; lipophilicity; molecular docking; SARS-CoV-2 proteins
1. Introduction
Nowadays, the search for new drugs requires the application of computational chem-
istry, including experimental and in silico analysis of physicochemical properties, phar-
macokinetic features, ADMET analysis, and quantitative structure–activity relationship
(QSAR) research [1,2]. The therapeutic potential of a drug depends on its distribution in
the body. Often, substances with high biological activity show low bioavailability and
high toxicity to healthy tissues. Nanocarriers, including liposomes, micelles, and polymer
nanoparticles, enable the improvement of the biodistribution of substances. Incorporation
of the hydrophobic core into hydrophilic nanotransporters can effectively influence the
solubility of the drug, which contributes to the improvement of permeability through cell
membranes [3,4].
A key parameter in the design of new active compounds is lipophilicity, which in-
fluences the solubility and permeability through membranes. Lipophilicity affects the
pharmacodynamic and toxicological profiles of compounds. These parameters can be deter-
mined experimentally or by using different calculation methods. Experimental lipophilicity
is usually determined by chromatographic methods, such as reversed phase thin layer chro-
matography (RP-TLC), normal phase thin layer chromatography (NP-TLC), or reversed
phase high performance liquid chromatography (RP-HPLC). Theoretical methods are the
second way to determine lipophilicity. However, the calculated value of lipophilicity
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depends on the algorithm employed for calculation, and for many compounds it differs
from the experimental ones [5–7].
Natural substances, especially secondary metabolites, are often an inspiration to obtain
semisynthetic compounds, which exhibit high biological activity. Microorganisms produce
many secondary metabolites that affect antibacterial, antiviral, and anticancer activities.
The Streptomyces species produce compounds containing the 5,8-quinolinedione moiety,
such as streptonigrin, lavendamycin, and streptonigron, which exhibit a wide spectrum of
biological activity (Figure 1) [8,9]. Previous studies dealt with the modification of 5,8-
quinolinedione moiety at the C-2, C-6, and C-7 positions and they showed that such
modification can lead to changes in biological activity [10–19].
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Figure 1. Chemical structure of 7-amino-5,8-quinolinedione antibiotics. 
Studies on the lipophilicity of 5,8-quinolinedione derivatives were carried out apply-
ing the RP-TLC and RP-HPLC methods. It was found that there is a relationship between 
lipophilicity and in silico pharmacokinetic properties of synthetic 5,8-quinolinedione de-
rivatives [20–23]. As a continuation of our previous research, we determined the lipo-
philicity experimentally as well as by using computational methods for the betulin tria-
zole derivatives with attached 1,4-quinone. The physicochemical and pharmacokinetic 
properties influence the bioavailability and biological activity of compounds when they 
are determined by computer programs. The correlation between lipophilicity and in silico 
determined structural parameters have been analyzed in this study. 
The tested compounds contain two active moieties, i.e., 1,4-quinone and betulin. The 
main mechanism of activity for 1,4-quinone derivatives is the interaction with NQO1 pro-
tein, for which the overexpression is observed in many types of cancer cell lines [8,10,24]. 
The betulin derivatives show a wide spectrum of activities including anticancer, antiviral, 
antibacterial, and anti-inflammatory effects. The use of betulin and its derivatives in treat-
ment is limited due to low bioavailability and low water solubility. For these reasons, the 
use of new drug nanoencapsulation procedures and/or nanoparticle-based delivery meth-
ods are a key issue. These are issues of nanomedicine interest [25,26]. 
Over the past decade, many betulin derivatives exhibiting high antiviral activity 
against human immunodeficiency virus (HIV-1), herpes simplex (HSV-1), enteric cyto-
pathogenic human orphan virus (ECHO-6), and human cytomegalovirus (HCMV) were 
described [27–31]. The high antiviral activity of betulin derivatives has aroused interest as 
a possibility of using them in the treatment of COVID-19 [32–35]. The aim of the present 
study was to characterize the triazole betulin derivatives with attached 1,4-quinone in 
terms of their lipophilicity, pharmacokinetic properties, and molecular docking with 
SARS-CoV-2 proteins, such as Mpro and PLpro. Moreover, we examined the correlation 
between scoring values (ΔG) and structural properties. 
2. Materials and Methods 
2.1. Data Set 
In this study, a series of triazole betulin derivatives with attached 1,4-quinone (1–16), 
as well as triazole betulin derivatives (17–20), were used. According to literature data [36], 
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Studies on the lipophilicity of 5,8-quinolinedione derivatives were carried out apply-
ing the RP-TLC and RP-HPLC methods. It was found that there is a relationship between
lipophilicity and in silico pharmacokinetic properties of synthetic 5,8-quinolinedione deriva-
tives [20–23]. As a continuation of our previous research, we determined the lipophilicity
experimentally as well as by using computational methods for the betulin triazole deriva-
tives with attached 1,4-quinone. The physicochemical and pharmacokinetic properties in-
fluence the bioavailability and biological activity of compounds when they are determined
by computer programs. The correlation between lipophilicity and in silico determined
structural parameters have been analyzed in this study.
The tested compounds contain two active moieties, i.e., 1,4-quinone and betulin.
The main mechanism of activity for 1,4-quinone derivatives is the interaction with NQO1
protein, for which the overexpression is observed in many types of cancer cell lines [8,10,24].
The betulin derivatives show a wide spectrum of activities including anticancer, antiviral,
antibacterial, and anti-inflammatory effects. The use of betulin and its derivatives in
treatment is limited due to low bioavailability and low water solubility. For these reasons,
the use of new drug nanoencapsulation procedures and/or nanoparticle-based delivery
methods are a key issue. These are issues of nanomedicine interest [25,26].
Over the past decade, many betulin derivatives exhibiting high antiviral activity
against human immunodeficiency virus (HIV-1), herpes simplex (HSV-1), enteric cy-
topathogenic human orphan virus (ECHO-6), and human cytomegalovirus (HCMV) were
described [27–31]. The high antiviral activity of betulin derivatives has aroused interest as
a possibility of using them in the treatment of COVID-19 [32–35]. The aim of the present
study was to characterize the triazole betulin derivatives with attached 1,4-quinone in
terms of their lipophilicity, pharmacokinetic properties, and molecular docking with SARS-
CoV-2 proteins, such as Mpro and PLpro. Moreover, we examined the correlation between
scoring values (∆G) and structural properties.
2. Materials and Methods
2.1. Data Set
In this study, a series of triazole betulin derivatives with attached 1,4-quinone (1–16),
as well as triazol b tulin derivatives (17–20), wer used. According to literature data [36],
the reaction between triazole betulin derivativ s (17–20) and 1,4-quinone compounds in the
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presence of potassium carbonate in tetrahydrofuran lead to the hybrids 1–16. The chemical
structures of compounds 1–20 are presented in Table 1.
Table 1. Chemical structure and biological activity of compounds 1–20.
Compound Chemical Structure Compound Chemical Structure
1
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2.2. Experimental Lipophilicity 
The experimental lipophilicity was determined using the RP-TLC method according 
to the literature [20,21,37]. We used the modified silica gel as a stationary phase and (tris-
hydroxymethyl)aminomethane (0.2 M, pH = 7.4) with acetone as a mobile phase. The per-
cent of organic solvent volume was varied within the range of 60–90% in 5% increments. 
The compounds 1–20 were dissolved in chloroform (1.0 mg/mL), then 5µL of sample 
solution was applied to the chromatographic plates with a micropipette. Spots were visu-
alized by spraying with 10% ethanol solution of sulfuric acid (VI) and then heated up to 
110 °C. 
The obtained values of retardation factor (Rf) were converted to RM parameters ac-
cording to Equation (1): R = log 1R − 1  (1) 
The RM parameter was calculated for every concentration of acetone and extrapolated 
to zero concentration of organic component in the mobile phase. The chromatographic 
parameter of lipophilicity (RM0) was calculated using Equation (2): R = R + 𝑏C (2) 
where C is the concentration of acetone in the mobile phase, while b is the slope of the 
regression plot. 
The hydrophobic index (φ0) was determined according to Equation (3): φ = −R𝑏  (3) 
2.3. Theoretical Lipophilicity 
For compounds 1–20, the calculated lipophilicity was determined using various 
online tools and free available software, including: ALOGPs, AClogP, AlogP, MLOGP, 
XLOGP2, XLOGP3 (German Research Center for Environmental Health, Neuherberg, 
Germany), milogP (Molinspiration Cheminformatics, Slovensky Grob, Slovak Republic), 
iLOGP, WLOGP, and SILICOS-IT (Swiss Institute of Bioinformatics, Lausanne, Switzer-
land) [38–41]. The pharmacokinetic and physiochemical parameters were determined us-
ing pKCMS (Bio21 Institute, Melbourne, Australia) and SwissADME software (Swiss In-
stitute of Bioinformatics, Lausanne, Switzerland) [40–43]. 
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using pKCMS (Bio21 Institute, Melbourne, Australia) and SwissADME software (Swiss
Institute of Bioinformatics, Lausanne, Switzerland) [40–43].
2.4. Structure Optimization
The optimized chemical structures of compounds 1–16 were calculated using the DFT
(B3LYP/6-311G+(d.p)) method implemented in the Gaussian 16 program package [44].
All local minima of energy were confirmed by the absence of an imaginary mode in
the vibrational calculations. In our calculations, we applied the basis set of the diffuse
function to heavy atoms (+) to obtain a better description of lone pair electrons with orbitals
occupying a larger region of space. The obtained optimized structure is presented in Figure
S1. The geometries of compounds 1–16 were used to determine the HOMO–LUMO energy,
quantum chemical descriptor, the molecular electrostatic potential, and the molecular
docking study [45]. All obtained results were visualized using the GaussView, Version 5
software package (Gaussian Inc., Wallingford, CT, USA) [46].
2.5. Molecular Docking Study
The three-dimensional (3D) structures (in mol2 format) of the studied compounds
were generated using the ChemOffice package (version 19.1, PerkinElmer, Waltham, MA,
USA) [47]. Their low-energy conformations were calculated using Gaussian 16 (revision
A.03) computer code [44] at the density functional theory (DFT, B3LYP) and 6-311+G(d,p)
basis sets. Calculations were performed using the X-ray coordinates of chloroquine as the
input structure obtained from the Cambridge Crystallographic Data Centre (CCDC ID:
CDMQUI).
Target macromolecule for molecular docking study was obtained from the Protein
Data Bank (https://www.rcsb.org/, accessed on 1 April 2020). We used the 3D crystal
structures of COVID-19 main protein and papain-like protease of SARS CoV-2 (PDB ID:
5R7Z and 6W9C, respectively).
Ligands and proteins used in the calculations were prepared for docking using the
AutoDockTools program (Molecular Graphics Laboratory, La Jolla, CA, USA) [48]. In
this study, AutoDock Vina [49] tool compiled in PyRx [50] was employed to perform
molecular docking. Implementing in AutoDock Vina scoring function was mostly inspired
by X-score and combined an empirical free-energy force field with a Lamarckian Genetic
Algorithm. The volume was set as 25 × 25 × 25 Å. The region of interest used for AutoDock
Vina docking was fixed as X = −33,784, Y = 20,933, Z = 33,306 for papain-like protease
and X = −11,631, Y = 2201, Z = 23,194 for COVID-19 main protein. After calculations,
only the nine highest-scored poses were returned as a docking result for ligand–cavity
configuration. The complexes obtained in the Vina program were visualized using the
BIOVIA Discovery Studio virtual environment (v.17.2.0.16349, Dassault systems, Vélizy-
Villacoublay, France) [51].
2.6. Correlation and Cluster Analysis
Based on the experimental and theoretical values of lipophilicity and molecular de-
scriptor values, the correlation and cluster analysis were performed. All data used for the
cluster analysis were standardized and the cluster analysis was based on the Euclidean
distance. The analysis was carried out using the Statistica 13.1 software (TIBCO Software
Inc., Palo Alto, CA, USA).
3. Results and Discussion
3.1. Experimental and Theoretical Lipophilicity
The hybrids 1–16 and substrates 17–20 were examined under the RP-TLC method.
For each compound, the parameter RM was calculated from the retardation factor (Rf)
according to Equation (1). Equation (2) was used to determine the RM0 and b values and
the results are presented in Table 2. The high correlation coefficients (r = 0.976–0.997) for all
compounds show good correlation between acetone concentration and RM value.
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Table 2. The experimental values of lipophilicity (RM0) for compounds 1–20.
Compound RM0 b r SD
1 3.51 −0.04 0.995 0.051
2 3.64 −0.04 0.992 0.067
3 3.97 −0.05 0.996 0.047
4 4.08 −0.05 0.992 0.072
5 3.56 −0.04 0.983 0.100
6 3.59 −0.04 0.997 0.041
7 4.07 −0.05 0.985 0.101
8 4.24 −0.05 0.993 0.065
9 3.65 −0.04 0.996 0.047
10 3.77 −0.04 0.996 0.048
11 4.12 −0.05 0.995 0.054
12 4.39 −0.05 0.981 0.115
13 3.78 −0.04 0.998 0.028
14 3.84 −0.04 0.992 0.067
15 4.21 −0.05 0.979 0.120
16 4.58 −0.05 0.960 0.183
17 4.40 −0.05 0.995 0.065
18 4.54 −0.05 0.989 0.098
19 5.07 −0.06 0.995 0.073
20 5.26 −0.06 0.976 0.161
b is the slope, r is the correlation coefficient, and SD is the standard deviation for the linear relationship RM = RM0 + bC.
The calibration curve is required for the conversion of RM0 to logPTLC. The following
compounds were used as standard substances: acetanilide, prednisone, 4-bromoacetophenone,
benzophenone, anthracene, dibenzyl, 9-phenylanthracene, and dichlorodiphenyltrichloroethane
(DDT), for which the literature values of logPlit are in the range 1.21–6.38 [52,53]. The RM0
for the standard substance was determined in the same conditions as for compounds 1–20
(Table 3).
Table 3. The experimental (RM0) and literature (logPlit) lipophilicity values of standard substance.
Compound logPlit RM0 b r SD logPTLC
Acetanilide 1.21 0.55 −0.01 0.954 0.051 1.19
Prednisone 1.63 0.73 −0.02 0.932 0.077 1.39
4-Bromoacetophenone 2.43 1.89 −0.03 0.993 0.037 2.72
Benzophenone 3.18 2.37 −0.03 0.993 0.046 3.26
Anthracene 4.45 3.48 −0.04 0.994 0.053 4.52
Dibenzyl 4.79 3.65 −0.04 0.997 0.043 4.72
DDT 6.01 4.87 −0.06 0.985 0.041 6.17
9-Phenylanthracene 6.38 4.93 −0.06 0.993 0.080 6.11
b is the slope, r is the correlation coefficient and SD is the standard deviation for the linear relationship RM = RM0 + bC.
The calibration curve Equation (4) was determined by linear correlation between the
logPlit and RM.
logPTLC = 1.139 RM0 + 0.561 (r = 0.996; SD = 0.188) (4)
For the standard substances the logPTLC was calculated according to the calibration
curve (Equation (4)). Figure S2 shows a good agreement between experimental and
literature values of lipophilicity (r = 0.996).
Equations (3) and (4) were used to determine the logPTLC and the hydrophobic index
(ϕ0), respectively. The results are presented in Figure 2 and Table S1.
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Table 4. Correlation equations for experimental (LogPTLC) and theoretical (LogPcalc) values of lip philici for compounds
1–16 and 17–20.
Program Correlation Equation r SD
Compounds 1–16
ALOGPs logPTLC = 1.094 logPCALC − 2.416 0.932 0.137
AClogP logPTLC = 0.540 logPCALC + 1.104 0.854 0.196
AlogP logPTLC = 0.492 logPCALC + 0.987 0.843 0.203
XLOGP2 logPTLC = 0.378 logPCALC + 1.268 0.854 0.196
XLOGP3 logPTLC = 0.472 logPCALC − 0.121 0.887 0.174
milogP logPTLC = 0.527 logPCALC + 0.549 0.729 0.258
iLOGP logPTLC = 0.758 logPCALC + 0.620 0.887 0.174
WLOGP logPTLC = 0.755 logPCALC − 2.091 0.953 0.114
MLOGP logPTLC = 0.582 logPCALC + 2.353 0.723 0.260
SILICOS-IT logPTLC = 0.634 logPCALC − 0.443 0.798 0.227
Compounds 17–20
ALOGPs logPTLC = 1.313 logPCALC − 1.485 0.980 0.114
AClogP logPTLC = 1.078 logPCALC − 0.058 0.962 0.157
AlogP logPTLC = 0.847 logPCALC + 0.25 0.962 0.232
XLOGP2 logPTLC = 0.567 logPCALC + 1.462 0.880 0.273
XLOGP3 logPTLC = 0.718 logPCALC − 0.097 0.929 0.213
milogP logPTLC = 0.766 logPCALC + 0.345 0.960 0.160
iLOGP logPTLC = 0.994 logPCALC + 0.916 0.924 0.220
WLOGP logPTLC = 1.083 logPCALC − 1.828 0.979 0.116
MLOGP logPTLC = 1.754 logPCALC − 3.543 0.955 0.170
SILICOS-IT logPTLC = 0.965 logPCALC − 0.092 0.815 0.332
The relationship between the lipophilicity and structure of compounds 1–20 was
analyzed by cluster analysis (Figure 4).
As shown in Figure 4, compounds 1–20 are arranged in two main clusters. The first
cluster consists of betulin derivatives 17–20 and the second one of hybrids 1–16. The high
value of Euclidean distance between two clusters suggests that there is a low correlation
between structures of these two groups of compounds.
The second cluster can be divided into four subclusters. In the first subcluster, the
hybrids are arranged according to the type of betulin moiety, which means that they have
oxo group at the C-3 position of the betulin moiety. The second and third subclusters
consist of 1,4-naphthoquinone (13, 15, and 16) and 5,8-quinolinedione moiety (5, 7, and 8),
respectively. Compounds containing the 5,8-quinolinedione (1, 3, and 4) and 2-methyl-5,8-
Pharmaceutics 2021, 13, 781 9 of 21
quinolinedione (9, 11, and 12) are included into the subcluster four. The similarity analysis
shows a strong correlation between lipophilicity and structure of hybrids 1–16.
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3.2. Physicochemical and Pharmacokinetic Properties
In the early drug discovery process, one of the important stages is to optimize the
physicochemical properties of a potential drug. Based on e observation of the physic-
ochemical properties of oral drugs, Lipinski formulated the Rule of Five. According to
this rul , the lipophilicity (logP), mol cular weight (MW), number of acceptors (HA), and
donors (HD) of hydrogen bo d should be a multiple of five [54]. In an attempt to impro
the prediction of bioavailability, the rules were expanded by Veber to the number of rotat-
able bonds (RB) and topological polar surface area (TPSA) are also determined [55,56]. The
molecular descriptors for tested hybrids 1–16 are presented in Table 5.
The tested hybrids 1–16 have a molecular mass above 500 g/mol, which means
they do not meet the mass criterion. All compounds have less than five hydrogen bond
donors (HD = 0–1). The 5,8-quinolinedione and 5,8-isoquinolinedione derivatives with
hydroxyl and oxo groups at C-3 position of betulin (1–2, 5–6, and 9–10) have less than
10 hydrogen bond acceptors (HA = 9–10) and the logPTLC less than 5, which means that
these compounds meet three of four Lipinski rules. Only compounds with propanoyl
substituents at the C-3 position of the betulin moiety (4, 8, 12, and 16) do not meet the
Veber’s rules concerning the number of rotatable bonds (RB < 10). The TPSA for 1–16 is
less than 140 Å, which determines the oral bioavailability.
For compounds 1–16, the relationship between the type of 1,4-quinone moiety, the
physicochemical parameters and experimental lipophilicity was analyzed by means of a
dendrogram (Figure 5).
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Table 5. Molecular descriptors for hybrids 1–16.
Compound MW (g/mol) HA HD RB TPSA (Å)
1 787.42 10 1 9 133.50
2 785.41 10 0 9 130.34
3 829.46 11 0 10 139.57
4 843.49 11 0 11 139.57
5 787.42 10 1 9 133.50
6 785.41 10 0 9 130.45
7 829.46 11 0 10 139.57
8 843.39 11 0 11 139.57
9 801.45 10 1 9 133.50
10 799.43 10 0 9 130.34
11 843.49 11 0 10 139.57
12 857.51 11 0 11 139.57
13 786.44 9 1 9 120.61
14 784.42 9 0 9 117.45
15 828.47 10 0 10 126.68
16 842.50 10 0 11 126.68
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The similarity analysis shows two main clusters. The first cluster consists of 1,4-
naphthoquinone derivatives (13 and 14) and the second one is divided into four subclusters.
Analysis of subclusters show that compounds with the 5,8-quinolinedione (1–4) and 2-
methyl-5,8-quinolinedione (5–8) exhibit similar properties. Comparing the properties
of 5,8-quinolinedione (1–4) and 5,8-isoquinolinedione (9–11) shows that the position of
nitrogen atom in heterocyclic ring influences their physicochemical parameters. The
similarity analysis shows that nitrogen atom significantly affects properties of the tested
derivatives.
The ultilinear regression ( LR) Equation (5) expresses the relationship between the
experimental lipophilicity (logPTLC) and physicochemical parameters, such as molecular
mass (MW), topological polar surface (TPSA), and number of rotatable bonds (RB).
logPTLC = 0.992MW − 0.488TPSA + 0.213RB − 3.362
(r = 0.985, r2 . , 1.11, VIF = 3.12, F = 126.7)
(5)
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The correlation coefficient shows good agreement between physicochemical param-
eters and experimental lipophilicity. A comparison of the experimental and calculated
parameters for the investigated compounds are shown in Table S3. The result shows that
lipophilicity could be determined by in silico parameters.
The physicochemical properties were used to in silico calculate the pharmacokinetic
parameters, which determine the absorption of the potential drug [57]. The prediction of
oral and transdermal absorption was performed in silico using the Caco-2 cell (logPapp),
human intestinal absorption (HIA), and skin permeability (logKp) models. Moreover, the
neurotoxicity of the compounds can be designated by blood–brain barrier permeability
(logBB) and central nervous system (logPS) penetration [12,58–60]. The pharmacokinetic
parameters of compounds 1–16 have been determined in silico by pkCSM software and
they are presented in Table 6.
Table 6. Pharmacokinetic parameters of hybrids 1–16.
Compound logBB logPS logKp logPapp HIA
1 −1.459 −2.481 −2.734 0.641 97.226
2 −1.581 −2.513 −2.735 0.639 98.193
3 −1.804 −2.442 −2.735 0.195 98.510
4 −1.831 −2.434 −2.735 0.215 98.358
5 −1.457 −2.466 −2.735 0.672 97.226
6 −1.579 −2.499 −2.735 0.671 98.193
7 −1.802 −2.428 −2.735 0.158 98.510
8 −1.830 −2.420 −2.735 0.178 98.358
9 −1.447 −2.443 −2.734 0.598 97.235
10 −1.569 −2.475 −2.735 0.597 98.090
11 −1.792 −2.404 −2.735 0.181 98.358
12 −1.820 −2.396 −2.735 0.200 98.231
13 −1.219 −2.215 −2.734 0.747 97.410
14 −1.341 −2.248 −2.735 0.745 97.838
15 −1.564 −2.177 −2.735 0.733 97.885
16 −1.592 −2.169 −2.735 0.728 97.879
According to the model used in the pkCMS software, if logPapp is more than 0.9,
it means that the compound expresses the high Caco-2 permeability [42]. For the tested
hybrids 1–12, the logPapp value is in the range 0.200–0.672, which means moderate Caco-2
permeability. In the series of 5,8-quinolinedione hybrids (1–12), compounds with hydroxyl
or oxo groups at the C-3 position of betulin moiety (1–2, 5–6, 9–10) have higher values of
logPapp than hybrids with acyl group at this position (3–4, 7–8, 11–12). In the group of
1,4-naphthoquinone compounds (13–16), the Caco-2 permeability does not depend on the
type of substituent at the C-3 position of the betulin moiety. Comparing the logPapp values
shows that the permeability depends on the type of 1,4-quinone moiety and the following
order is fulfilled: 1,4-naphthoquinone > 5,8-quinolinedione > 2-metyl-5,8-quionolinedione
> 5,8-isoquinolnedione. For 1–16 the human intestinal absorption (HIA) are in the range of
(97.226–98.510), which are considered to be high. The HIA index slightly depends on the
type of 1,4-quinonemoiety. Hybrids 1–16 have a moderate skin permeability because they
have the logKp lower than −2.5.
For 1–16, the logBB are lower than −1, which means these hybrids poorly cross the
brain–blood barrier. Compounds do not pass into the central nervous system when the
logPS is less than −2. This result shows that the tested derivatives 1–16 are not neurotoxic.
The similarity analysis showed no correlation between pharmacokinetic parameters
and the structure of compounds 1–16 (Figure S3). However, the cluster analysis showed
that only betulin moiety influences the pharmacokinetic parameters of hybrids.
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3.3. Molecular Properties
The energy of HOMO and LUMO orbitals determines the ability of the molecule to
donated or receive an electron. The energy of orbitals can be used to calculate the global
reactivity descriptors, such as: ionization potential (I), electron affinity (A), hardness (η),
chemical potential (µ), electronegativity (χ), and electrophilicity index (ω) [61].
The HOMO and LUMO orbitals of 1–16 are presented in Figure S4. Table 7 shows the
HOMO and LUMO energy, the energy gap (∆E = EHOMO − ELUMO), the global reactivity
descriptors, and dipole moment (DM).


















1 −6.227 −3.918 −2.310 6.227 3.918 1.155 −5.073 5.073 11.140 5.6507
2 −6.510 −3.989 −2.521 6.510 3.989 1.261 −5.250 5.250 10.930 9.563
3 −6.423 −3.980 −2.443 6.423 3.980 1.222 −5.202 5.202 11.076 6.3035
4 −6.422 −3.984 −2.438 6.422 3.984 1.219 −5.203 5.203 11.106 6.5282
5 −6.503 −3.816 −2.687 6.503 3.816 1.344 −5.159 5.159 9.906 5.8305
6 −6.228 −3.869 −2.360 6.228 3.869 1.180 −5.049 5.049 10.801 8.9646
7 −6.421 −3.867 −2.554 6.421 3.867 1.277 −5.144 5.144 10.359 6.548
8 −6.426 −3.866 −2.560 6.426 3.866 1.280 −5.146 5.146 10.345 6.4041
9 −6.499 −4.151 −2.348 6.499 4.151 1.174 −5.325 5.325 12.078 6.7295
10 −6.248 −4.183 −2.065 6.248 4.183 1.032 −5.216 5.216 13.176 7.2985
11 −6.450 −4.162 −2.288 6.450 4.162 1.144 −5.306 5.306 12.306 4.5204
12 −6.450 −4.165 −2.285 6.450 4.165 1.142 −5.307 5.307 12.328 4.6037
13 −6.485 −3.786 −2.699 6.485 3.786 1.349 −5.135 5.135 9.772 7.0345
14 −6.239 −3.816 −2.424 6.239 3.816 1.212 −5.027 5.027 10.428 8.3989
15 −6.428 −3.792 −2.637 6.428 3.792 1.318 −5.110 5.110 9.903 5.0970
16 −6.442 −3.793 −2.649 6.442 3.793 1.325 −5.117 5.117 9.885 5.6097
For all compounds 1–16, the LUMO orbitals are mainly delocalized at the 1,4-quinone
moiety. Localization of HOMO orbitals depends on the type of substituent at the C-3
position of the betulin moiety. The HOMO orbitals of hybrids with hydroxy and acyl
groups (1, 3–5, 7–9, 11–13, and 15–16) at the C-3 position are mainly delocalized at the
isopropenyl group and A ring of betulin. For hybrids with the oxo group (2, 6, 10, and
14), these orbitals are delocalized at the D ring and oxo group (Figure S4). The molecular
properties influence the reactivity and stability of molecules. The high value of EHOMO
and low value of ELUMO show that the compounds are highly reactive with nucleophilic
molecules. The energy gap ∆E depends on the van der Waals interaction between molecules
and its value could be correlated with the biological activity of the compounds [62,63]. The
hybrids 1, 5, 9, and 13 are characterized by the lowest chemical hardness and the highest
negative value of chemical potential, which means they are comparatively soft with high
polarizability compared with other compounds in this series.
The arrangement of nucleophilic and electrophilic regions of a molecule influences
its interaction with a biological target through hydrogen bonds and hydrophobic interac-
tions. The distribution of the positive and negative charges of molecule is described by
the molecular electrostatic potential map (MEP) [64,65]. The different charges are repre-
sented by different colors, which means that the red, blue, and green areas are negative,
positive, or neutral, respectively [66]. The MEP’s are sketched for an order of (−47,935) to
47,935 kcal/mol. The maps for hybrids 1, 5, 9, and 13 present in Figure 6, while for the rest
of the compounds, they are shown in Figure S5.
For all hybrids 1–16, the nucleophilic regions (red color) are localized in four main
area. The first and second areas are localized on 1,4-quinone moiety. The first area contains
the carbonyl atom at C-5 and the second area the carbonyl group at C-8, and the nitrogen
atom. The third area includes the triazole linker, and the fourth, the substituent at the C-3
position of the betulin moiety. The electrophilic regions (blue color) are localized near the
methine group at 1,4-quinone moiety and the methylene group at the triazole linker, while
the betulin regions are neutral (Figure 6 and Figure S5).
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sition of the betulin moiety. The HOMO orbitals of hybrids with hydroxy and acyl groups 
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Figure 6. Molecular electrostatic potential plotted for hybrids: (a) 1, (b) 5, (c) 9, and (d) 13. 
For all hybrids 1–16, the nucleophilic regions (red color) are localized in four main 
area. The first and second areas are localized on 1,4-quinone moiety. The first area con-
tains the carbonyl atom at C-5 and the second area the carbonyl group at C-8, and the 
nitrogen atom. The third area includes the triazole linker, and the fourth, the substituent 
at the C-3 position of the betulin moiety. The electrophilic regions (blue color) are localized 
near the methine group at 1,4-quinone moiety and the methylene group at the triazole 
linker, while the betulin regions are neutral (Figures 6 and S5). 
In each area, the local minima have been determined for 1–16, and they are collected 
in Table S4. The analysis of the local minima in the first, third, and fourth areas show that 
the arrangement of charges does not depend on the type of 1,4-quinone moiety. However, 
in the second area, the amount of potential minima depends on the type of 1,4-quinone 
moiety, i.e., the hybrids with 5,8-quinolinedione or 5,8-isoquinolinedione moiety have 
two potential minima, but compounds with 1,4-naphthoquinone moiety have only one 
potential minima in this area (Table S4). 
3.4. Molecular Docking Study 
Since the end of 2019, coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, 
has infected many people around the word. The World Health Organization (WHO) esti-
mated that up to April 2021 more than 142 million people tested positive for COVID-19 
and more than 3 million people died from this virus [67]. At the beginning of the pan-
demic, attempts were made to treat with chloroquine, but this treatment was halted and 
now chloroquine is not recommended (Figure 6) [68]. Contemporary reports indicate the 
effective use of amantadine and remdesivir in the treatment of patients with SARS-CoV-
2 (Figure 7) [69,70]. 
Continuing our research on molecular docking to SARS-CoV-2 targets, we examined 
the interaction between hybrids 1–16 and Mpro and PLpro proteins using the AutoDock 
Vina program (referred to as Vina). As reference ligands, chloroquine, amantadine, and 
remdesivir were used (Figure 7). 
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Continuing our research on molecular docking to SARS-CoV-2 targets, we examined
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Vina program (referred to as Vina). As reference ligands, chloroquine, amantadine, and
remdesivir were used (Figure 7).
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The results obtained with the use of the Vina program are presented in Table 8. The
lower the ∆G energy, the better the affinity of the tested ligands for the receptor. Calcu-
lations of the Ki from the binding energy of the pose generated by Vina were performed
using Equations (6) and (7).
∆G














∆G pKI ∆G pKI ∆G pKI ∆G pKI
1 −8.8 6.46 −8.3 6.09 11 −9.3 6.82 −6.4 4.70
2 −8.9 6.53 −6.9 5.06 12 −9.1 6.68 −7.0 5.14
3 −8.6 6.31 −6.5 4.77 13 −8.6 6.31 −7.6 5.58
4 −7.8 5.72 −6.5 4.77 14 −8.6 6.31 −8.2 6.02
5 −8.8 6.46 −7.9 5.80 15 −8.6 6.31 −6.4 4.70
6 −8.9 6.53 −8.1 5.94 16 −8.4 6.16 −7.0 5.14
7 −8.0 5.87 −6.9 5.06 Chloroquine −5.7 4.18 −5.2 3.82
8 −8.5 6.24 −6.4 4.70 Remdesivir −7.4 5.43 −5.7 4.18
9 −9.1 6.68 −8.1 5.94 Amantadine −4.5 3.30 −4.1 3.01
10 −9.2 6.75 −6.8 4.99
Based on the obtained results, it can be concluded that the tested derivatives show
docking scores in the range of −9.3 to −7.8 and −8.3 to −6.4 for Mpro and PLpro, respec-
tively. The obtained ∆G are lower compared to the reference compounds (−7.4 to −4.5
and −5.7 to −4.1 for Mpro and PLpro, respectively). This indicates that in preliminary in
silico studies, hybrids 1–16 show a higher affinity for the proteins used than the reference
drugs. Comparing the score values of hybrids 1–16 with betulin-5,8-quinolinedione deriva-
tives [18] showed that the introduction of triazole linker between betulin and 1,4-quinone
increased the ∆G value for Mpro and PL pro proteins.
The main protease Mpro, also known as 3CLpro, is one of the coronavirus nonstruc-
tural proteins (Nsp5). Inhibition of Mpro would prevent the virus from replication and as
a consequence, Mpro is one of the coronavirus proteins designated as potential targets for
drug development. According to the crystallographic data, amino acids His41, Met49, and
residues 164–168 of the long strand play an important role in stabilizing the ligand-Mpro
complexes [71].
As seen in Figure 8a, the hybrids are localized in the hydrophobic matrix of the
protein, but the arrangement depends on the type of the 1,4-quinone moiety. Comparing
the score values for Mpro protein shows that in the series of 5,8-quinolinedione (1–4) and
5,8-isoquinolinedione (5–8), the highest ∆G values exhibit derivatives with oxo group at the
C-3 position of betulin moiety. In the group of 2-methyl-5,8-quinolinedione, better docking
scores are obtained for hybrids 10 and 11. However, in the series of 1,4-naphthoquinone
derivatives (13–16), the group at the C-3 position of the betulin moiety does not influence
the ∆G.
Ligands 2, 6, and 14, which have the best score values, contain the same betulin moiety
but different 1,4-quinone fragments. In the group of 2-methyl-5,8-quinolinedione hybrids,
the lowest ∆G has hybrid 11. For detailed analysis of molecular docking, complexes of the
Mpro with 2, 6, 10, 11, and 14 ligands have been chosen. Complete models of the possible
interaction in 3D and 2D views are presented in Figure 9a,e and Figure S6A–E. The detailed
data about the type and length of the binding interactions between these ligands and the
protein residues are summarized in Table S5.
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Comparing the arrangement of hybrids 2, 6, 10 in the active site of the protein shows
that the position of nitrogen atoms in the 5,8-quinolinedione moiety influences the inter-
action between the ligand and the hydrophobic matrix of protein. As seen in Figure 9a,c
and Table S5, ligands 2 and 10 create the hydrogen bond and hydrophobic interaction
between 1,4-quinone moiety and His41, Asn142, Gly143, and Cys145. In these complexes,
the betulin moiety is stabilized by hydrophobic interaction with Pro168. Changing the
5,8-quinolinedione ring to 5,8-isoquinolinedione moiety causes different arrangement of
the ligand in the hydrophobic matr x. In complex Mpro-hybrid 6, the itrogen atom and tri-
azole ring creat the hydro en bond and hydrophobic interaction with Pro168 and Asn142,
Glu166, Leu141, respectively (Figure 9b and Figure S7B). In this case, betulin is bound to
Met49, Met165, and His41 by hydrophobic interaction. The 1,4-naphthoquione moiety
(hybrid 14) interacts with His41, Cys145, Met165, and Gln189 by hydrophobic interaction.
Moreover, the triazole unit and betulin moiety are stabilized by hydrophobic interaction
with Cys145 and Pro168, respectively (Figure 9e and Figure S6E).
Figure 9d and Figure S6D present the possible interaction of the best fitted compound
11 inside the binding pocket of Mpro. Corresponding amino aci s that are significantly
involved in the hyd ophobic interactions betwee ligand and the betulin unit are as follows:
His41, Met49, and Met165. Moreover, the whole complex is additi nally stabilized by
the hydrophobic interactions of the newly introduced substituents: the triazole unit with
Glu166 and the 1,4-quinone moiety with Leu167 and Pro168.
It should be emphasized that the 1,4-quinone moiety plays an important role in the
stabilization of Mpro hybrid complexes.
One of the attractive antiviral drug targets is the SARS-CoV-2 papain-like protease
PLpro which is responsible for processing three cleavage sites of the viral polyprotein to
release mature nonstructural proteins 1, 2, and 3. In the case of PLpro, the drug molecules
bind to S3/S4 d mains. The S3/S4 pocket contains the residues Asp164, Val165, Arg166,
Glu167, Met208, Ala246, P o247, Pro248, Tyr264, Gly266, Asn267, Tyr268, Gln269, Cys217,
Gly271, Tyr273, Thr301, and Asp302 [72].
As seen in Figure 8b, the hybrids are localized in the hydrophobic matrix of the protein,
but the type of 1,4-quinone slightly influences the arrangement of the hybrid in the pocket
site of proteins. Comparing the score values for PLpro protein shows that in the group
of 5,8-quinolinedione hybrids (1–4 and 9–12) the highest values have derivatives with
hydroxy group at the C-3 position of betulin moiety, while in the series of 5–8 and 13–16
the best results are obtained for hybrids with the oxo group at this position.
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In each group of 1,4-quinone, we chose one of the best ∆G, and performed detailed
analysis for it. Complete models of the possible interaction in 3D and 2D views are
presented in Figure 10a–d and Figure S7A–D. The detailed data about the type and length
of the binding interactions between these ligands and the protein residues are summarized
in Table S5.
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Comparing the optimal docking post of compounds 1, 6, and 9 shows a general
trend that the betulin moiety is bound to Pro248 and Lue162 by hydrophobic interaction
(Figure 10a–c and Figure S7A–C). The hydroxyl or carbonyl group at the C-3 position
creates a hydrogen bond with Thr301 (1) or Arg166 (6 and 9). The 1,4-quinone moiety and
triazole ring are involved in hydrophobic interaction with Pro248 and Tyr268, respectively.
Hybrid with 1,4-naphtoquinone 14 has a different arrangement in the active site of
PLpro than these with 5,8-qui olinedione or 5,8-isoquinolinedione ligands (Figure 10d and
Figure S7D). The 1,4-quinone moiety creates two hydroge bonds with Lys157 and one
with Gly163. The complex is stabilized by hydroph bic interaction with Leu162, Pro248,
Met208, and Tyr264. In this case, the triazole ring does not interact with the hydrophobic
matrix of enzyme.
As indicated by literature date, the molecular, physicochemical, and pharmacokinetic
properties can be used to determine the biological activity of the compounds [73,74]. The
MLR analysis allows to find correlation between score values (∆G), experimental lipophilic-
ity and in silico determined parameters. The MLR equation (8) shows the correlation
between the score value for Mpro, experimental lipop ilicity (logPTLC), number of rotat-
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able bonds (RB), and the energy of LUMO (ELUMO) orbitals. The ∆G for PLpro correlates
with molecular mass (M), number of acceptors of hydrogen bond (HA), and energy of
HOMO (EHOMO) orbitals (Equation (9)).
∆GMpro = −0.65 logPTLC + 1.04 RB + 0.624 ELUMO − 3.052
(r = 0.788, r2 = 0.621, SD = 0.281, F = 6.559, p = 0.007)
(8)
∆GPLpro = 0.280 M − 0.57 HA + 0.38 EHOMO − 30.306
(r = 0.844, r2 = 0.712, SD = 0.135, F = 9.894, p = 0.001)
(9)
The obtained results show that the physicochemical and molecular properties of tested
hybrids influence their interaction with the SARS-CoV-2 proteins.
4. Conclusions
In the presented study, the lipophilicity of betulin triazole derivatives with attached 1,4-
quinone moiety was determined and analyzed in terms of structure, physicochemical, and
pharmacokinetic parameters. Comparing the lipophilicity of betulin triazole derivatives
and hybrids with attached 1,4-quinone, the introduction of 1,4-quinone moiety reduces the
lipophilicity. The cluster analysis showed a correlation between the molecular structure
of hybrids and their experimental and calculated lipophilicity that can be used to predict
these values when designing new compounds. The bioavailability of the tested compound
was described by pharmacokinetic and physicochemical properties using the Lipinski and
Veber rules. The obtained in silico parameters showed that most of the hybrids could be
applied orally and they did not exhibit the neurotoxic activity.
For compounds with attached 1,4-quinone, the LUMO orbitals were mainly delocal-
ized at the 1,4-quinone moiety. Localization of HOMO orbitals depended on the type of
substituent at the C-3 position of the betulin moiety. The molecular properties depended
on the type of 1,4-quinone moiety. The molecular electrostatic potential showed that the
negative potential sites are present in the nucleophilic atoms, i.e., nitrogen and oxygen
atoms. The arrangement of the charge depends on the type of 1,4-quinone moiety.
The molecular docking study showed that betulin triazole derivatives with attached
1,4-quinone can inhibit selected SARS-CoV-2 proteins. The high affinity score values of
Mpro and PLpro proteins resulted from the introduction of the triazole ring as a linker
connecting the betulin moiety with the 1,4-quinone fragment. The multilinear regression
equation showed the correlation between the score values for Mpro and PLpro proteins,
and experimental lipophilicity (logPTLC), molecular descriptors, and global properties. The
study showed that the determination of these parameters allows for the prediction of the
interactions between the ligand and SARS-CoV-2 proteins.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13060781/s1, Table S1. The experimental of lipophilicity (logPTLC) and
hydrophobic index (ϕ0) for compounds 1–20, Table S2. The calculated lipophilicity for compounds
1–20, Table S3. The experimental and predicted logP, Table S4. The local minima of hybrids 1–16,
Table S5. Interaction of hybrids 1, 2, 6, 9, 10, 11, and 14 with active site of Mpro and PL protein,
Figure S1. The optimized structure of hybrids 1–16, Figure S2. The linear regression between the
experimental and literature lipophilicity for standard substance, Figure S3. The similarity analysis of
pharmacokinetic parameters of hybrids 1–16, Figure S4. The HOMO and LUMO orbitals for hybrids
1–16, Figure S5. The MEP for hybrids 1–16, Figure S6. Docking pose of COVID-19 Mpro protein
complex with hybrids 2 (A), 6 (B), 10 (C), 11 (D), and 14 (E), Figure S7. Docking pose of COVID-19
PLpro protein complex with hybrids 1 (A), 6 (B), 9 (C), and 14 (D).
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